PDPL

The Exchange had sought clarification from Parenteral Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone limited review report not submitted. -2. Consolidated limited review report not submitted. The response of the Company is enclosed.

The Exchange has sought clarification from Parenteral Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted. -2. Consolidated limited review report not submitted. The response of the Company is awaited.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.

Parenteral Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

Parenteral Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

Parenteral Drugs (India) Limited has informed the Exchange regarding Notice of Postal Ballot

Parenteral Drugs (India) Limited has informed the Exchange that A meeting of the Board of Directors of the company was held on Friday, the 22nd day of December, 2017 at 03.05 P.M. at the Corporate Office of the Company at Indore and concluded at 7.10 P.M. The Board inter-alia considered and approved to seek approval of shareholders by way of postal ballot in terms of section 180 and 188 of the Companies Act, 2013, the Rules framed there under and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for sale/transfer of Kasrawad and WFI

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on December 22, 2017.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

Parenteral Drugs (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2017. Further, the company has informed the Exchange regarding voting results.

Parenteral Drugs (India) Limited has informed the Exchange regarding Change in Auditors of the company.

Parenteral Drugs (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2017

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books will remain closed from September 23, 2017 to September 29, 2017 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 29, 2017.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 23, 2017 to September 29, 2017 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held September 29, 2017.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

Parenteral Drugs (India) Limited has informed the Exchange the resignation of Mr. Dilip Kumar Panchaity as an Independent Director on the Board of the Company w.e.f May, 01, 2017 pursuant to intimation of such resignation received by the Company on May 01, 2017.

SBICAP Trustee Company Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011..

Parenteral Drugs (India) Limited has informed the Exchange regarding Voting Result of Postal Ballot.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of the Postal Ballot Notice,

Parenteral Drugs (India) Limited has informed the Exchange regarding Limited Review Report for the Quarter ended December 31, 2016

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome of Board Meeting of the Company held on February 13, 2017.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Parenteral Drugs (India) Limited has submitted to the Exchange the details of voting results of the Extra-Ordinary General Meeting of the members of the Company to be held on November 21, 2016.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of the proceedings of the Extra-Ordinary General Meeting of the Company held on November 21, 2016.

PDPL: The Exchange had sought clarification from Parenteral Drugs (India) Limited with respect to announcement dated 14-Nov-2016, regarding "Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 14, 2016 had considered & approved the appointment of Mr. Sandeep Vyas as an additional and Independent director on the Board of the Company.".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of

PDPL:The Exchange has sought clarification from Parenteral Drugs (India) Limited with respect to announcement dated 14-Nov-2016, regarding "Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 14, 2016 had considered & approved the appointment of Mr. Sandeep Vyas as an additional and Independent director on the Board of the Company.".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of

Parenteral Drugs (India) Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 14, 2016 had considered & approved the appointment of Mr. Sandeep Vyas as an additional and Independent director on the Board of the Company.

Parenteral Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Parenteral Drugs (India) Limited has informed the Exchange that the register of members and share transfer books will be closed from November 15, 2016 to November 21, 2016 (both days inclusive) for the purpose of Extra-Ordinary General Meeting to be held on November 21, 2016.

Parenteral Drugs (India) Limited has informed the Exchange regarding Outcome Board Meeting held on October 21, 2016.

Parenteral Drugs (India) Limited has informed the Exchange that in respect of Company's Code of Conduct to regulate, Monitor and report trading by insiders for prevention of Insider Trading in the Equity shares and for the aforesaid purpose the " Trading WIndow" of the Company shall remain closed from the date of intimation October 14, 2016 to October 23, 2016 and will open on October 24, 2016 for insiders accordingly.

Parenteral Drugs (India) Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the September 26, 2016 along with Report of Scrutinizer.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 26, 2016.

Parenteral Drugs (India) Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 20, 2016 to September 26, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 26, 2016.

Parenteral Drugs (India) Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended June 30, 2016.

Parenteral Drugs (India) Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

Parenteral Drugs (India) Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

Parenteral Drugs (India) Limited has informed the Exchange that As per the provisions of regulation 9 and Schedule B of the SEBI (Prohibition of Insider Trading) Regulations, 2015, in respect of Company s Code of Conduct to regulate, monitor and report trading by insiders for Prevention of Insider Trading in the Equity shares and for the aforesaid purpose the "Trading Window" of the Company shall remain closed from the date of intimation i.e. May 21, 2016 to June 01, 2016 and will open on June 02, 2016 for insiders accordingly.

Rajratan exports private limited has submitted to the Exchange vide letter dated April 5, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

SBICAP Trustee Company Ltd. has submitted to the Exchange vide letter dated April 05, 2016 a copy of disclosure under Regulation 30(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parenteral Drugs (India) Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended December 31, 2015.

Parenteral Drugs (India) Limited has informed the Exchange that As per the provisions of regulation 9 and Schedule B of the SEBI (Prohibition of Insider Trading) Regulations, 2015, in respect of Company's Code of Conduct to regulate, monitor and report trading by insiders for Prevention of Insider Trading in the Equity shares and for the aforesaid purpose the "Trading Window" of the Company shall remain closed from the date of intimation i.e. February 04, 2016 to February 15, 2016 and will open on February 16, 2016 for insiders accordingly.

Parenteral Drugs (India) Limited has informed the Exchange that a meeting of the Board of Directors of the company was held on December 30, 2015 at the Corporate Office of the Company at Indore. The Board inter-alia considered and approved the disinvestment of equity shares held by the Company in its non-operational Subsidiary Companies i.e. Parentech Healthcare Limited and Parenteral Surgicals Limited as the same are loss making companies, and accorded its in-principle approval to declare the non-working Subsidiaries of the company i.e. Abhay Drugs Limited, Anjaney Pharmaceuticals Limited, Pa

Parenteral Drugs (India) Limited has informed the Exchange that the "Trading Window" of the Company shall remain closed from the date of intimation i.e. December 26, 2015 to January 01, 2016 and will open on January 02, 2016 for insiders accordingly.

Parenteral Drugs (India) Limited has submitted to the Exchange a Clarification on Outcome of Board Meeting held on November 9, 2015.

Parenteral Drugs (India) Limited has submitted to the Exchange a copy of the Un-audited Financial Results (both Standalone and Consolidated) of the company for the quarter ended September 30, 2015. (Revised)

Parenteral Drugs (India) Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Parenteral Drugs (India) Limited has informed the Exchange that the "Trading Window" of the Company shall remain closed from October 31, 2015 to November 11, 2015 and will open on November 12, 2015 for insiders accordingly.

Clarification by Parenteral Drugs (India) LimitedSignificant price movement has been observed in Parenteral Drugs (India) Limited.The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Parenteral Drugs (India) Limitedhas vide its letter inter-alia stated, "accordingly to clause 36 of the Listing agreement the company does not have any information which is required to be informed to the exchange and members that have a bearing on the operati